See more : Aravali Securities & Finance Limited (ARAVALIS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of MGC Pharmaceuticals Limited (MGCLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MGC Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Ester Industries Limited (ESTER.NS) Income Statement Analysis – Financial Results
- VIRIDIEN (VIRI.PA) Income Statement Analysis – Financial Results
- Daishi Hokuetsu Financial Group, Inc. (7327.T) Income Statement Analysis – Financial Results
- COLTENE Holding AG (0QP7.L) Income Statement Analysis – Financial Results
- Cardinal Ethanol, LLC (CRDE) Income Statement Analysis – Financial Results
MGC Pharmaceuticals Limited (MGCLF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://mgcpharma.com.au
About MGC Pharmaceuticals Limited
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. The company also provides ArtemiC range of products and cannabinoid products, as well as non-pharma products. In addition, it offers consulting services, including clinical research services. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is based in West Perth, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.39M | 4.65M | 2.96M | 2.03M | 656.24K | 296.81K | 120.24K | 2.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Cost of Revenue | 1.94M | 3.01M | 1.65M | 1.90M | 356.64K | 119.34K | 158.07K | 15.01K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.45M | 1.63M | 1.31M | 130.15K | 299.60K | 177.47K | -37.83K | -12.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 351.66K | 2.11M | 1.91M | 2.63M | 0.00 |
| Gross Profit Ratio | 42.82% | 35.15% | 44.23% | 6.40% | 45.65% | 59.79% | -31.46% | -583.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 1.99M | 4.24M | 5.86M | 5.37M | 2.87M | 951.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.13M | 8.28M | 5.73M | 6.61M | 2.61M | 3.36M | 4.27M | 683.09K | 510.09K | 244.11K | 362.77K | 101.01K | 98.33K | 1.43M | 1.70M | 1.39M | 1.03M | 0.00 |
| Selling & Marketing | 926.91K | 949.83K | 583.19K | 562.13K | 574.98K | 612.76K | 204.76K | 240.26K | 36.39K | 12.33K | 9.38K | 3.16K | 4.83K | 223.63K | 326.02K | 477.93K | 462.40K | 0.00 |
| SG&A | 13.06M | 9.23M | 6.31M | 6.61M | 3.19M | 3.97M | 4.47M | 923.35K | 546.48K | 256.43K | 372.16K | 104.17K | 103.17K | 1.65M | 2.03M | 1.86M | 1.49M | 0.00 |
| Other Expenses | -578.77K | -1.18M | -425.12K | 524.32K | 9.46M | -1.79M | -1.29M | -1.78M | -6.51K | 1.60K | -27.35K | 15.00K | 28.39K | 951.09K | 155.02K | 27.97K | 2.59M | 0.00 |
| Operating Expenses | 17.05M | 15.08M | 13.38M | 12.55M | 9.34M | 7.44M | 7.28M | 4.36M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Cost & Expenses | 24.26M | 18.10M | 15.03M | 14.45M | 9.70M | 7.56M | 7.44M | 4.38M | 3.80M | 5.35M | 765.21K | 343.94K | 252.45K | 3.08M | 3.64M | 3.55M | 2.68M | 0.00 |
| Interest Income | 240.00 | 300.00 | 7.63K | 12.34K | 201.85K | 191.59K | 127.26K | 46.03K | 5.89K | 7.10K | 25.66K | 38.06K | 7.12K | 759.08K | 390.37K | 27.97K | 40.94K | 0.00 |
| Interest Expense | 257.40K | 190.05K | 369.14K | 135.58K | 8.00K | 99.37K | 19.72K | 120.01K | 0.00 | 0.00 | 0.00 | 0.00 | 95.14K | 1.74M | 573.54K | 11.34K | 25.89K | 0.00 |
| Depreciation & Amortization | 751.94K | 504.30K | 491.41K | 481.13K | 259.74K | 328.11K | 83.52K | 16.58K | 0.00 | 0.00 | 8.33K | 0.00 | 0.00 | 166.64K | 35.47K | 47.60K | 40.48K | 0.00 |
| EBITDA | -14.69M | -15.16M | -12.00M | -13.04M | -8.45M | -8.54M | -8.40M | -6.09M | -3.80M | -5.35M | -756.87K | -343.94K | -216.95K | -855.93K | -1.34M | -1.57M | -55.88K | 0.00 |
| EBITDA Ratio | -455.34% | -303.90% | -404.87% | -443.15% | 134.22% | -2,875.65% | -6,984.90% | -277,354.48% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -243.40% | -63.32% | -82.21% | -2.13% | 0.00% |
| Operating Income | -15.23M | -14.63M | -12.49M | -9.50M | 621.07K | -8.86M | -8.48M | -6.11M | -3.80M | -5.35M | -765.21K | -343.94K | -216.95K | -1.02M | -1.37M | -1.61M | -96.37K | 0.00 |
| Operating Income Ratio | -449.72% | -314.75% | -421.46% | -466.80% | 94.64% | -2,986.19% | -7,054.36% | -278,109.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -290.78% | -65.00% | -84.70% | -3.67% | 0.00% |
| Total Other Income/Expenses | -5.90M | -1.64M | -1.59M | -7.48M | 6.84M | -1.94M | -1.21M | -2.01M | -166.94K | -2.65K | -27.35K | 53.06K | -232.49K | -2.16M | -573.54K | -11.34K | 14.60K | 0.00 |
| Income Before Tax | -21.13M | -17.14M | -13.53M | -18.81M | -1.88M | -8.99M | -8.50M | -6.23M | -3.80M | -5.34M | -766.90K | -290.88K | -449.44K | -3.18M | -1.95M | -1.63M | -81.77K | 0.00 |
| Income Before Tax Ratio | -623.80% | -368.81% | -456.71% | -924.70% | -285.93% | -3,029.02% | -7,070.76% | -283,571.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -904.30% | -92.17% | -85.30% | -3.11% | 0.00% |
| Income Tax Expense | 2.02K | -1.36M | -27.28K | 1.21M | 27.32K | -1.04K | -1.63M | -1.73M | 0.00 | 0.00 | -25.66K | 0.00 | -117.28K | 2.14M | 728.55K | 251.84K | 2.57M | 0.00 |
| Net Income | -20.82M | -16.77M | -13.97M | -19.36M | -2.31M | -8.25M | -8.14M | -6.16M | -3.80M | -5.34M | -766.90K | -290.88K | 1.94M | -2.63M | -1.95M | -1.88M | -81.77K | 0.00 |
| Net Income Ratio | -614.71% | -360.79% | -471.33% | -951.67% | -351.91% | -2,778.31% | -6,773.31% | -280,252.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -748.06% | -92.17% | -98.51% | -3.11% | 0.00% |
| EPS | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.40 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| EPS Diluted | -7.07 | -6.53 | -7.33 | -14.01 | -1.91 | -7.33 | -8.43 | -10.20 | -13.43 | -33.37 | -11.83 | -11.25 | 156.00 | -326.13 | -244.95 | -236.36 | -11.07 | 0.00 |
| Weighted Avg Shares Out | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.81K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
| Weighted Avg Shares Out (Dil) | 2.95M | 2.57M | 1.91M | 1.38M | 1.21M | 1.13M | 966.34K | 603.56K | 282.81K | 159.96K | 64.81K | 25.86K | 12.40K | 8.07K | 7.94K | 7.94K | 7.39K | 7.39K |
Argent BioPharma hails US listing; appoints new CFO
Argent BioPharma Ltd (LSE:MXC, OTC:MGCLF, ASX:RGT) is trading on the OTCQB Venture Market effective May 2 under the ticker symbol MGCLF, which it plans to change. This transatlantic presence aims to enhance accessibility and liquidity for investors through cross-trading, allowing American transactions in US dollars...
MGC Pharma reports progress 'across all fronts'
MGC Pharma experienced growth across all fronts in the six months to end December 2023, according to Roby Zomer, co-founder and managing director. “MGC secured a substantial order worth US$1 million from AMC Pharma for the production of ArtemiC,” he...
MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation
Embracing Comprehensive Restructuring for a New Biopharmaceutical Era Continuing the Development of MGC Pharma's Innovative Drug Portfolio LONDON , Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC) Rebrands as Argent BioPharma in Strategic TransformationMarking...
MGC Pharmaceuticals unveils fundraise as global push planned
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has announced a US$500,000 fundraise via a private placement amid a new push to expand its global footprint. Some 1,480,000 ordinary shares at AU$0.50 (US$0.34) each will be issued under the plan, MGC Pharma...
MGC Pharmaceuticals granted Saudi FDA approval for ArtemiC™
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has been granted approval for its proprietary product ArtemiC™ by the Food and Drug Authority (FDA) in the Kingdom of Saudi Arabia as an over-the-counter (OTC) dietary supplement. The approval follows the success of Phase...
MGC Pharma receives Saudi approval for ArtemiC
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC), the pharma company known for its focus on creating innovative medicines, has announced a significant milestone: its product ArtemiC has received approval from the Food and Drug Authority in the Kingdom of Saudi Arabia. This marks...
MGC Pharmaceuticals clarifies share consolidation and new fundraise
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has provided clarity on the company's consolidation of capital and new fundraising programme. Further to Thursday's news of a $7.9 million ($12.46 million) equity round, the group has confirmed that on completion of the...
MGC Pharmaceuticals proposes financial and capital restructuring plan
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said directors have been forced to propose a financial and capital restructuring plan to secure long-term financing due to the extreme difficulties in raising funds on the stock market this year. The plan, including...
MGC Pharmaceuticals hails pivot to medical products, legacy sales hit
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) hailed a "year of great productivity" as it pivoted to medicinal products, with legacy sales hit by a change in legislation in Australia. Medicinal product sales rose to A$1.9 million in from A$1.55 million...
MGC Pharmaceuticals proposes fundraising for Australian investors
MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) said it is looking to raise up to A$2.7 million (£1.39 million) via a share purchase plan for its Australian shareholders. The new cash will be used for production, raw material and laboratory costs associated with...
Source: https://incomestatements.info
Category: Stock Reports